Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | CTX-8371 |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | colon cancer | sensitive | CTX-8371 | Preclinical | Actionable | In a preclinical study, CTX-8371 treatment resulted in greater tumor growth inhibition than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) in a syngeneic mouse model of colon cancer expressing CD274 (PD-L1), with tumor regression in 62.5% (5/8) of the treated mouse models (PMID: 38379869). | 38379869 |
PubMed Id | Reference Title | Details |
---|---|---|
(38379869) | A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. | Full reference... |